Bovhyaluronydaza azoksymer | Longidaza suppositories vaginal and rectal 3000 IU 20 pcs.
Special Price
$79.38
Regular Price
$88.00
In stock
SKU
BID527741
Pharmacological action of
The prolongation of the action of the enzyme is achieved by covalent binding of the enzyme to a physiologically active polymer carrier (azo oximer). LongidazaВ® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases, depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor-alpha), increases the humoral immune response and the body's resistance to infection.
The pronounced antifibrotic properties of Longidases are provided by conjugation of hyaluronidase with a carrier, which significantly increases the enzyme's resistance to denaturing and inhibitory effects: the enzymatic activity of Longidase is preserved by heating to 37 РC for 20 days, while native hyaluronidase loses under these conditions activity during the day.
The LongidazaВ® preparation provides simultaneous local presence of the hyaluronidase enzyme and a carrier capable of binding the enzyme inhibitors and stimulants of collagen synthesis (iron, copper, heparin, etc.) released upon hydrolysis of the matrix components. Due to these properties, LongidazaВ® possesses not only the ability to depolymerize the connective tissue matrix in fibro-granulomatous formations, but also suppress the reverse regulatory reaction aimed at the synthesis of connective tissue components.
A specific substrate for testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix.
As a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or indoronic acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water, metal ions decreases, the permeability of tissue barriers temporarily increases, the movement of fluid in the intercellular space is facilitated, the elasticity of the connective tissue increases, which manifests itself in a decrease in swelling of the tissue, flattening of scars, an increase in the volume of movement of the joints, a decrease in contractures and the prevention of their formation, and a decrease in adhesions.
Biochemical, immunological, histological and electron microscopic studies have proved that Longidaza® does not damage normal connective tissue, but causes destruction of the connective tissue, which has been changed in composition and structure, in the area of ​​fibrosis.
LongidazaВ® does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.
The drug is well tolerated by patients, there are no local and general allergic reactions.
The use of Longidase in therapeutic doses during or after surgical treatment does not cause a deterioration in the postoperative period or the progression of the infectious process does not slow down bone restoration.
The prolongation of the action of the enzyme is achieved by covalent binding of the enzyme to a physiologically active polymer carrier (azo oximer). LongidazaВ® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases, depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor-alpha), increases the humoral immune response and the body's resistance to infection.
The pronounced antifibrotic properties of Longidases are provided by conjugation of hyaluronidase with a carrier, which significantly increases the enzyme's resistance to denaturing and inhibitory effects: the enzymatic activity of Longidase is preserved by heating to 37 РC for 20 days, while native hyaluronidase loses under these conditions activity during the day.
The LongidazaВ® preparation provides simultaneous local presence of the hyaluronidase enzyme and a carrier capable of binding the enzyme inhibitors and stimulants of collagen synthesis (iron, copper, heparin, etc.) released upon hydrolysis of the matrix components. Due to these properties, LongidazaВ® possesses not only the ability to depolymerize the connective tissue matrix in fibro-granulomatous formations, but also suppress the reverse regulatory reaction aimed at the synthesis of connective tissue components.
A specific substrate for testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix.
As a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or indoronic acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water, metal ions decreases, the permeability of tissue barriers temporarily increases, the movement of fluid in the intercellular space is facilitated, the elasticity of the connective tissue increases, which manifests itself in a decrease in swelling of the tissue, flattening of scars, an increase in the volume of movement of the joints, a decrease in contractures and the prevention of their formation, and a decrease in adhesions.
Biochemical, immunological, histological and electron microscopic studies have proved that Longidaza® does not damage normal connective tissue, but causes destruction of the connective tissue, which has been changed in composition and structure, in the area of ​​fibrosis.
LongidazaВ® does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.
The drug is well tolerated by patients, there are no local and general allergic reactions.
The use of Longidase in therapeutic doses during or after surgical treatment does not cause a deterioration in the postoperative period or the progression of the infectious process does not slow down bone restoration.
Pharmacological action of
The prolongation of the action of the enzyme is achieved by covalent binding of the enzyme to a physiologically active polymer carrier (azo oximer). LongidazaВ® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases, depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor-alpha), increases the humoral immune response and the body's resistance to infection.
The pronounced antifibrotic properties of Longidases are provided by conjugation of hyaluronidase with a carrier, which significantly increases the enzyme's resistance to denaturing and inhibitory effects: the enzymatic activity of Longidase is preserved by heating to 37 РC for 20 days, while native hyaluronidase loses under these conditions activity during the day.
The LongidazaВ® preparation provides simultaneous local presence of the hyaluronidase enzyme and a carrier capable of binding the enzyme inhibitors and stimulants of collagen synthesis (iron, copper, heparin, etc.) released upon hydrolysis of the matrix components. Due to these properties, LongidazaВ® possesses not only the ability to depolymerize the connective tissue matrix in fibro-granulomatous formations, but also suppress the reverse regulatory reaction aimed at the synthesis of connective tissue components.
A specific substrate for testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix.
As a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or indoronic acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water, metal ions decreases, the permeability of tissue barriers temporarily increases, the movement of fluid in the intercellular space is facilitated, the elasticity of the connective tissue increases, which manifests itself in a decrease in swelling of the tissue, flattening of scars, an increase in the volume of movement of the joints, a decrease in contractures and the prevention of their formation, and a decrease in adhesions.
Biochemical, immunological, histological and electron microscopic studies have proved that Longidaza® does not damage normal connective tissue, but causes destruction of the connective tissue, which has been changed in composition and structure, in the area of ​​fibrosis.
LongidazaВ® does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.
The drug is well tolerated by patients, there are no local and general allergic reactions.
The use of Longidase in therapeutic doses during or after surgical treatment does not cause a deterioration in the postoperative period or the progression of the infectious process does not slow down bone restoration.
Indications
Adults and adolescents over 12 years of age as monotherapy and as part of the complex treatment of diseases accompanied by connective tissue hyperplasia, including against the background of the inflammatory process:
in urology: chronic prostatitis, interstitial cystitis, urethral and ureter strictures, Peyronie’s disease, the initial stage of benign prostatic hyperplasia, prevention of scarring and stricture after surgery on the urethra, urinary bladder, ureter
in gynecology: adhesive process (prophylaxis and treatment) in chronic inflammatory diseases of the internal genital organs, after gynecological manipulations, including artificial abortions, previous surgical interventions elstv pelvic adhesions intrauterine bodies tuboperitoneal infertility, chronic endomyometritis
in dermatology: Limited scleroderma, prevention of fibrotic complications of infections, sexually transmitted
in surgery: prevention and treatment of the adhesive process after surgical interventions on the abdominal cavity organs for a long time unhealed
wounds in pulmonology and phthisiology: pneumofibrosis, siderosis, tuberculosis (cavernous-fibrous, infiltrative, tuberculoma), interstitial pneumonia, fibrosing alveolitis, pleuritis for pleuritis urology, gynecology, dermatovenerology, surgery, pulmonology, etc.
Contraindications
increased individual sensitivity to drugs with hyaluronidase activity, Longidase®
malignant neoplasms
pregnancy (no clinical experience)
children under 12 years of age (efficacy and safety have not been studied).
Precautions (use no more than 1 time per week): a history of renal failure, pulmonary hemorrhage.
Special instructions
Discontinue use of Longidase® in case of an allergic reaction.
When used against the background of exacerbation of foci of infection, to prevent the spread of infection, prescribe under the guise of antimicrobial agents.
Composition
Composition per suppository:
Active ingredient:
Bovgyaluronidase azoximerВ® Lon
Excipient:
cocoa butter - until a suppository weighing 1.3 g is obtained
Dosage and administration
rectally, 1 supp. 1 time per day after bowel cleansing.
Vaginally, 1 time per day (at night) 1 supp. inserted into the vagina in a prone position.
Longidaza® Suppositories 3000 ME is recommended in a course of 10 to 20 injections.
The schedule of administration is adjusted depending on the severity, stage and duration of the disease: Longidaza® is prescribed every other day or with interruptions of 2-3 days.
Recommended regimens and doses:
- in urology: 1 supp. every day - 10 introductions, then after 2-3 days - 10 introductions, with a general course of 20 supp.
- in gynecology: rectally or vaginally, 1 supp. after 2 days - 10 injections, then, if necessary, maintenance therapy
is prescribed - in dermatovenereology: 1 supp. after 1-2 days - 10-15 injections of
- in surgery: 1 supp. after 2-3 days - 10 injections of
- in pulmonology and phthisiology: 1 supp. after 2–4 days, 10–20 administrations.
If necessary, a repeated course of Longidase® is recommended no earlier than 3 months or long-term maintenance therapy - 1 supp. 1 time in 5-7 days for 3-4 months.
Side effects
Rarely - allergic reactions with increased individual sensitivity.
Active ingredient
Bovgyaluronidase azo oximer
Terms of delivery from
pharmacies Without a prescription
Formulation
rectal suppositories
Appointment by
Adult by doctor's appointment, Children by doctor's appointment, Children over 12 years old
NPO Petrovaks Pharm, Russia
The prolongation of the action of the enzyme is achieved by covalent binding of the enzyme to a physiologically active polymer carrier (azo oximer). LongidazaВ® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases, depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor-alpha), increases the humoral immune response and the body's resistance to infection.
The pronounced antifibrotic properties of Longidases are provided by conjugation of hyaluronidase with a carrier, which significantly increases the enzyme's resistance to denaturing and inhibitory effects: the enzymatic activity of Longidase is preserved by heating to 37 РC for 20 days, while native hyaluronidase loses under these conditions activity during the day.
The LongidazaВ® preparation provides simultaneous local presence of the hyaluronidase enzyme and a carrier capable of binding the enzyme inhibitors and stimulants of collagen synthesis (iron, copper, heparin, etc.) released upon hydrolysis of the matrix components. Due to these properties, LongidazaВ® possesses not only the ability to depolymerize the connective tissue matrix in fibro-granulomatous formations, but also suppress the reverse regulatory reaction aimed at the synthesis of connective tissue components.
A specific substrate for testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix.
As a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or indoronic acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water, metal ions decreases, the permeability of tissue barriers temporarily increases, the movement of fluid in the intercellular space is facilitated, the elasticity of the connective tissue increases, which manifests itself in a decrease in swelling of the tissue, flattening of scars, an increase in the volume of movement of the joints, a decrease in contractures and the prevention of their formation, and a decrease in adhesions.
Biochemical, immunological, histological and electron microscopic studies have proved that Longidaza® does not damage normal connective tissue, but causes destruction of the connective tissue, which has been changed in composition and structure, in the area of ​​fibrosis.
LongidazaВ® does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.
The drug is well tolerated by patients, there are no local and general allergic reactions.
The use of Longidase in therapeutic doses during or after surgical treatment does not cause a deterioration in the postoperative period or the progression of the infectious process does not slow down bone restoration.
Indications
Adults and adolescents over 12 years of age as monotherapy and as part of the complex treatment of diseases accompanied by connective tissue hyperplasia, including against the background of the inflammatory process:
in urology: chronic prostatitis, interstitial cystitis, urethral and ureter strictures, Peyronie’s disease, the initial stage of benign prostatic hyperplasia, prevention of scarring and stricture after surgery on the urethra, urinary bladder, ureter
in gynecology: adhesive process (prophylaxis and treatment) in chronic inflammatory diseases of the internal genital organs, after gynecological manipulations, including artificial abortions, previous surgical interventions elstv pelvic adhesions intrauterine bodies tuboperitoneal infertility, chronic endomyometritis
in dermatology: Limited scleroderma, prevention of fibrotic complications of infections, sexually transmitted
in surgery: prevention and treatment of the adhesive process after surgical interventions on the abdominal cavity organs for a long time unhealed
wounds in pulmonology and phthisiology: pneumofibrosis, siderosis, tuberculosis (cavernous-fibrous, infiltrative, tuberculoma), interstitial pneumonia, fibrosing alveolitis, pleuritis for pleuritis urology, gynecology, dermatovenerology, surgery, pulmonology, etc.
Contraindications
increased individual sensitivity to drugs with hyaluronidase activity, Longidase®
malignant neoplasms
pregnancy (no clinical experience)
children under 12 years of age (efficacy and safety have not been studied).
Precautions (use no more than 1 time per week): a history of renal failure, pulmonary hemorrhage.
Special instructions
Discontinue use of Longidase® in case of an allergic reaction.
When used against the background of exacerbation of foci of infection, to prevent the spread of infection, prescribe under the guise of antimicrobial agents.
Composition
Composition per suppository:
Active ingredient:
Bovgyaluronidase azoximerВ® Lon
Excipient:
cocoa butter - until a suppository weighing 1.3 g is obtained
Dosage and administration
rectally, 1 supp. 1 time per day after bowel cleansing.
Vaginally, 1 time per day (at night) 1 supp. inserted into the vagina in a prone position.
Longidaza® Suppositories 3000 ME is recommended in a course of 10 to 20 injections.
The schedule of administration is adjusted depending on the severity, stage and duration of the disease: Longidaza® is prescribed every other day or with interruptions of 2-3 days.
Recommended regimens and doses:
- in urology: 1 supp. every day - 10 introductions, then after 2-3 days - 10 introductions, with a general course of 20 supp.
- in gynecology: rectally or vaginally, 1 supp. after 2 days - 10 injections, then, if necessary, maintenance therapy
is prescribed - in dermatovenereology: 1 supp. after 1-2 days - 10-15 injections of
- in surgery: 1 supp. after 2-3 days - 10 injections of
- in pulmonology and phthisiology: 1 supp. after 2–4 days, 10–20 administrations.
If necessary, a repeated course of Longidase® is recommended no earlier than 3 months or long-term maintenance therapy - 1 supp. 1 time in 5-7 days for 3-4 months.
Side effects
Rarely - allergic reactions with increased individual sensitivity.
Active ingredient
Bovgyaluronidase azo oximer
Terms of delivery from
pharmacies Without a prescription
Formulation
rectal suppositories
Appointment by
Adult by doctor's appointment, Children by doctor's appointment, Children over 12 years old
NPO Petrovaks Pharm, Russia
Write Your Own Review